Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium gluconate + zinc gluconate + lysine hydrochloride (commonly referred to in China as Glucose Calcium Zinc Oral Solution or 葡萄糖钙锌口服溶液) is an approved oral fixed-dose combination supplement. Developed and manufactured by Hubei Wushi Pharmaceutical (and marketed under brands such as Fuwa), this combination product is formulated as an oral solution. It contains calcium gluconate, zinc gluconate, and lysine hydrochloride as its active ingredients. It is primarily indicated for the treatment and prevention of calcium and zinc deficiencies, supporting bone development, improving appetite, promoting growth, and treating conditions such as rickets, osteomalacia, osteoporosis, growth retardation in children, anorexia, recurrent oral ulcers, and acne.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium gluconate + zinc gluconate + lysine hydrochloride.